Enable Injections, Inc. ("Enable"), a healthcare innovation company developing and manufacturing the enFuse(R) On-Body Delivery System, today announced that the EMPAVELI(R) Injector, based on enFuse ...

WILMINGTON, Del. & CINCINNATI, October 27, 2025--(BUSINESS WIRE)--Incyte (NASDAQ:INCY) and Enable Injections, Inc. ("Enable") today announced a new partnership to develop and commercialize specific ...

CINCINNATI, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. ("Enable”), a healthcare innovation company developing and manufacturing the enFuse® on-body drug delivery system, announced today ...

CINCINNATI, March 25, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® wearable drug delivery platform, today ...

CINCINNATI (WKRC) - A company in Evendale is changing medicine through a breakthrough device that gives patients a way to take certain medications at home. Its purpose is to redefine drug delivery.

Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® On-Body Delivery System, today announced that the EMPAVELI ® Injector, based on enFuse ...

Under the terms of the agreement, Incyte will obtain a worldwide, exclusive license to use the enFuse technology with its mutCALR-targeted therapy (INCA033989) in essential thrombocythemia (ET) and ...

Collaboration underscores both companies’ commitment to advancing patient-centric solutions and expanding access to therapies through novel drug delivery technologies Under the terms of the agreement, ...